We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Hydrogel Endovascular Aneurysm Treatment Trial (HEAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01407952
Recruitment Status : Completed
First Posted : August 2, 2011
Results First Posted : June 27, 2019
Last Update Posted : June 27, 2019
MicroVention, Inc.
Information provided by (Responsible Party):
Bernard Bendok, Northwestern University

Brief Summary:

This research study is being done to test the effectiveness of a new generation FDA approved device for treating aneurysms compared to the current standard device for endovascular aneurysm treatment which is bare platinum coils. Endovascular procedures are a form of minimally invasive surgery, which is performed on blood vessels. The technique involves the introduction of a catheter which is a long, thin, flexible, hollow plastic tube through the skin into a large blood vessel. Typically the chosen blood vessel is the femoral artery found near the groin. The catheter is then maneuvered through the body to the location of the aneurysm in the brain using image guidance. Coils are delivered into the aneurysm through the catheters. Once the coils are delivered in the aneurysm, they are detached from the catheter. This is repeated until enough coils fill the aneurysm, blocking the blood flow to the aneurysm. The body responds by forming blood clots around the coil(s), which helps block the flow of blood into the aneurysm and keeps the vessel from rupturing or leaking. This study will compare the study device to the standard bare platinum coil to see which is better at preventing future rupturing or leaking. The study device is called the HydroCoil Embolization System and this study is a post-market clinical trial.

About 600 subjects from multiple institutions will take part in this study.

Condition or disease Intervention/treatment Phase
Cerebral Aneurysm Device: HydroCoil Embolic System Device: Control (bare platinum coils) Not Applicable

Detailed Description:

Your part in this study will last up to 24 months and will involve 6 visits (1 baseline visit before your surgery, the surgical procedure and 4 follow-up visits). These visits will occur at the same time as the visits you would receive as standard of care after your surgery.

If you are in this study, you will be placed in one of two study groups by chance using a process similar to the flip of a coin. This process is called randomization. Neither you nor the study staff will select the group you will be in. One group, the control group, will have their aneurysm treated by the bare platinum coils during their endovascular procedure. The other group, the study group will receive coils from the HydroCoil Embolization System. Both groups will receive the same standard of care and follow-up, but during the surgery different types of coils will be used.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: New Generation Hydrogel Endovascular Aneurysm Treatment Trial
Study Start Date : April 2012
Actual Primary Completion Date : March 2018
Actual Study Completion Date : March 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Aneurysms

Arm Intervention/treatment
HydroCoil Embolic System
Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
Device: HydroCoil Embolic System
HydroCoil Embolic System
Other Name: MicroVention, Inc

Aneurysm treatment using bare platinum coil(s)
Device: Control (bare platinum coils)
bare platinum coils

Primary Outcome Measures :
  1. Number of Patients With Aneurysm Recurrence Post Surgery [ Time Frame: post surgery to 24 months ]
    Defined as any progression on the Raymond-Roy (RR) Aneurysm Occlusion Scale. The RR scale is such that 1=complete occlusion, 2=residual neck, and 3=residual aneurysm.

Secondary Outcome Measures :
  1. Packing Density [ Time Frame: at operation ]
    Packing density as measured by volumetric filling of the aneurysm

  2. Clinical Outcome: Modified Rankin Scale (mRS) [ Time Frame: 24 months ]
    modified rankin scale is a measure of neurological disability, which ranges from 0=no symptoms to 5=severe disability (6=dead).

  3. Number of Participants With Adverse Events Related to the Procedure and/or the Device by Participant at Any Time in the Study. [ Time Frame: 24 months ]
    number of participants who experienced any peri-procedural or post-procedural Adverse Event noted to be related to the procedure or device.

  4. Total Number of Peri-procedural and Post-procedural Adverse Events Related to the Procedure and/or the Device. [ Time Frame: 24 months ]
    total number of Adverse Events per person that were noted to be related to the procedure and device during the study

  5. Number of Patients Who Expired During the Study (Mortality Rate) [ Time Frame: 24 months ]
    all-cause mortality at any time during study follow-up

  6. Number of Participants With Initial Complete Occlusion [ Time Frame: at procedure ]
    Raymond-Roy (RR) Scale=1 at procedure The RR scale is such that 1=complete occlusion, 2=residual neck, and 3=residual aneurysm.

  7. Number of Patients Who Needed Re-treatment of Target Aneurysm [ Time Frame: 24 months ]
    During the 24 month follow-up, if Aneurysm needed to be re-treated.

  8. Number of Participants Experiencing a Hemorrhage From Target Aneurysm Post Surgery [ Time Frame: 24 months ]
    Per the Adverse event log, if a hemorrhage or rupture occurred that was noted to be related to the procedure or device at any point during the 24 month follow-up (not during the operation).

  9. Number of Participants Who Progressed on the Meyers Scale [ Time Frame: 24 months ]
    Occlusion (in)stability was determined by progression on the Meyers scale. The Meyer scale is a 6-point grading scale based on the percentage of the aneurysm filled by contrast on DSA. Grade zero indicates complete and total aneurysm occlusion without remnant or in-terstitial filling within the aneurysm. Grade 1 represents greater than 90%volumetric occlusion of the aneurysm based on planar imaging assessment; grade 2, 70%-89% aneurysm occlusion; grade 3,50%-69%; grade 4, 25%-49%; and grade 5, less than 25% volumetric aneurysm occlusion.

  10. Number of Participants Experiencing Major Versus Minor Recurrence by 24 Months Follow-up. [ Time Frame: 24 months ]

    Major recurrence is defined as progression on the Raymond-Roy (RR) Scale to 3, or if initial RR was 3, then progression on the Meyers scale. Minor recurrence was defined as a progression on the RR scale to 2.

    The RR scale is a 3 point measure of occlusion, 1=total, 2=residual neck, and 3=residual aneurysm.

    The Meyer scale is a 6-point grading scale based on the percentageof the aneurysm filled by contrast on DSA. Grade zero indicates complete and total aneurysm occlusion without remnant or in-terstitial filling within the aneurysm. Grade 1 represents >90%volumetric occlusion of the aneurysm based on planar imaging assessment; grade 2, 70%-89% aneurysm occlusion; grade 3,50%-69%; grade 4, 25%-49%; and grade 5, <25% volumetric aneurysm occlusion.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Candidates for this study must meet the following criteria to be enrolled in the study:

  1. Patient is between 18 and 75 years of age (inclusive).
  2. Patient has a documented untreated intracranial saccular aneurysm 3-14 mm diameter angiographic lumen, ruptured or unruptured, suitable for embolization with coils.
  3. Patients presenting with a HUNT and HESS Grade 0-3 or improving to such a grade before treatment
  4. Any type of bare platinum coils and HydroCoil ® Coils are treatment options (all shapes allowed).
  5. Patient or next of kin or person with appropriate power of attorney has provided written informed consent.
  6. Patient is willing and available for study follow-up visits
  7. Patient has not been previously entered into this Study

Exclusion Criteria:

Candidates will be ineligible for enrollment in the study if any of the following conditions apply:

  1. Inability to obtain informed consent
  2. Patient is < 18 or > 75 years old
  3. Target aneurysm is not saccular in nature (mycotic, fusiform, dissecting).
  4. Target aneurysm is > 14 mm maximum luminal dimension, < 3 mm maximum luminal dimension
  5. Target aneurysm has been previously clipped or coiled
  6. Target aneurysm is in the physician's estimate unlikely to be successfully treated by endovascular techniques.
  7. Patient has known hypersensitivity to platinum, nickel, stainless steel or structurally related compounds found in HydroCoil®, HydroSoft®, HydroFrame® Coils and/or bare platinum coils.
  8. Baseline Hunt and Hess scale 4 or 5 for ruptured aneurysms
  9. Intended use of a flow diverting stent (e.g. pipeline)
  10. Subject has concurrent intracranial pathology, e.g.

    • Moyamoya
    • Vasculitis documented by biopsy results
    • AVMs
    • AV fistulas
    • Significant atherosclerotic disease (i.e. symptomatic and or >50% narrowing of the parent arteries necessary to traverse in order to coil the target aneurysm)
    • Intracranial Hematoma (unrelated to the target aneurysm)
    • Brain tumors
    • Vascular tortuosity and other conditions preventing access to target aneurysm
  11. Subject has serious co-morbidities that could confound the study results:

    • Uncontrolled hypertension
    • Uncorrectable coagulation abnormality
    • Contraindications for heparin, aspirin or clopidogrel
    • Uncontrolled Diabetes Mellitus
    • Organ failure of kidney, liver, heart, or lung
    • Myocardial infarction within the past 6 months
    • Cancer likely to cause death within 2 years or less.
  12. Subject history indicates high risk of non-compliance (e.g., substance abuse, psychosocial issues, etc.)
  13. Subject has a known history contraindicating contrast dye or iodine that cannot be pre-medicated prior to coiling procedure (vs. sensitivity which can be safely controlled by antihistamine, steroid, etc.). Medical clearance will be needed for this issue.
  14. Patients who are unable to complete scheduled follow up assessments at the enrolling center due to limited life expectancy (<2 years), co-morbidities or geographical considerations
  15. Subject is currently breast feeding, pregnant or plans to become pregnant in the next 2 years.
  16. Major surgical procedure or trauma within 30 days prior to randomization
  17. The patient is currently enrolled in another clinical study (device or drug).
  18. More than one aneurysm needing treatment at the same time.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01407952

Show Show 44 study locations
Sponsors and Collaborators
Northwestern University
MicroVention, Inc.
Layout table for investigator information
Principal Investigator: Bernard R Bendok, MD Mayo Clinic
  Study Documents (Full-Text)

Documents provided by Bernard Bendok, Northwestern University:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bernard Bendok, MD, Northwestern University
ClinicalTrials.gov Identifier: NCT01407952    
Other Study ID Numbers: HEAT_protocol1
First Posted: August 2, 2011    Key Record Dates
Results First Posted: June 27, 2019
Last Update Posted: June 27, 2019
Last Verified: June 2019
Keywords provided by Bernard Bendok, Northwestern University:
treatment trial
cerebral aneurysm
bare platinum
Additional relevant MeSH terms:
Layout table for MeSH terms
Intracranial Aneurysm
Vascular Diseases
Cardiovascular Diseases
Intracranial Arterial Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases